Caxton Corporation’s Satsuma Pharmaceuticals STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-68,172
Closed -$1.96M – 19
2020
Q2
$1.96M Sell
68,172
-538,148
-89% -$12.5M 2.07% 9
2020
Q1
$13M Sell
606,320
-52,932
-8% -$1.2M 14.26% 3
2019
Q4
$13M Sell
659,252
-211,568
-24% -$3.01M 12.51% 3
2019
Q3
$13.1M Buy
+870,820
New +$13.5M 14.74% 2

Other funds holding STSA

Caxton Corporation's STSA Position: Q3 2020 in Review

Caxton Corporation sold out of Satsuma Pharmaceuticals (STSA) in Q3 2020, closing a stake of 68,172 shares — an estimated $1.96M sold.

Caxton Corporation first reported a position in STSA in Q3 2019 and held it in 4 quarters. The position peaked at $13.1M in Q3 2019. 46 funds tracked by Wall St. Rank hold STSA as of Q3 2020.

  • Caxton Corporation reported no remaining Satsuma Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Caxton Corporation sold 68,172 Satsuma Pharmaceuticals shares in Q3 2020, an estimated $1.96M.
  • Caxton Corporation first reported a position in Satsuma Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Caxton Corporation's Satsuma Pharmaceuticals position peaked at $13.1M in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals as of Q3 2020.

Based on Caxton Corporation's 13F filing for Q3 2020, filed 16 Nov 2020.